6:34 PM
 | 
Feb 18, 2009
 |  BC Extra  |  Financial News

Celera falls on guidance

Celera (NASDAQ:CRA) fell $2.47 (26%) to $6.87 on Wednesday after giving guidance below analysts' expectations. The genomics and proteomics company said it expects mid-single digit non-GAAP EPS...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >